Oxford Science Park based Nucleome is harnessing its ability to read the "dark genome" to develop therapies for inflammatory disease and beyond

blonca9
Sep 17, 2024
1 min read

Updated: Sep 18, 2024

New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how he thinks Nucleome is in a unique position to put it into practice.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Oxford Science Park based Nucleome is harnessing its ability to read the "dark genome" to develop therapies for inflammatory disease and beyond

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight